The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study

Abstract

Objective:

The objective of this study was to explore the potential causal associations of body mass index, height, weight, fat mass, fat percentage and non-fat mass in the whole body, arms, legs and trunk (henceforth, ‘anthropometric measures’) with multiple sclerosis (MS) risk and severity. We also investigated the potential for reverse causation between anthropometric measures and MS risk.

Methods:

We conducted a two-sample univariable, multivariable and bidirectional Mendelian randomisation (MR) analysis.

Results:

A range of features linked to obesity (body mass index, weight, fat mass and fat percentage) were risk factors for MS development and worsened the disease’s severity in MS patients. Interestingly, we were able to demonstrate that height and non-fat mass have no association with MS risk or MS severity. We demonstrated that the association between anthropometric measures and MS is not subject to bias from reverse causation.

Conclusions:

Our findings provide evidence from human genetics that a range of features linked to obesity is an important contributor to MS development and MS severity, but height and non-fat mass are not. Importantly, these findings also identify a potentially modifiable factor that may reduce the accumulation of further disability and ameliorate MS severity.

Keywords

Multiple sclerosis Mendelian randomisation multiple sclerosis severity anthropometric obesity disability progression

Get full access to this article

View all access options for this article.

References

Gremese

Tolusso

Gigante

, et al. Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol 2014; 5: 576.

De Heredia

Gómez-Martínez

Marcos

. Obesity, inflammation and the immune system. Proceedings of the Nutrition Society 2012; 71: 332–338.

Mohammad

Aziz

Al Mahri

, et al. Obesity and COVID-19: What makes obese host so vulnerable? Immunity & Ageing 2021; 18: 1–10.

Munger

Chitnis

Ascherio

. Body size and risk of MS in two cohorts of US women. Neurology 2009; 73: 1543–1550.

Hedström

Olsson

Alfredsson

. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18(9): 1334–1336.

Mokry

Ross

Timpson

, et al. Obesity and multiple sclerosis: A Mendelian randomization study. PLoS Med 2016; 13: e1002053.

Harroud

Mitchell

Richardson

, et al. Childhood obesity and multiple sclerosis: A Mendelian randomization study. Mult Scler 2021; 27(14): 2150–2158.

Pilutti

Motl

. Body composition and disability in people with multiple sclerosis: A dual-energy x-ray absorptiometry study. Mult Scler Relat Disord 2019; 29: 41–47.

Frankenfield

Rowe

Cooney

, et al. Limits of body mass index to detect obesity and predict body composition. Nutrition 2001; 17(1): 26–30.

10.

Speed

Jefsen

Børglum

, et al. Investigating the association between body fat and depression via Mendelian randomization. Translational Psychiatry 2019; 9: 1–9.

11.

Jonnalagadda

Skinner

Moore

. Overweight athlete: Fact or fiction? Curr Sport Med Rep 2004; 3: 198–205.

12.

Wingo

Young

Motl

. Body composition differences between adults with multiple sclerosis and BMI-matched controls without MS. Disabil Health J 2018; 11(2): 243–248.

13.

Richter

Cutter

Pandey

, et al. Body mass index correlates with multiple sclerosis disease and symptom severity in women, but not in men. Neurol Disord Therap 2017; 1: 1–5.

14.

Lambert

Lee Archer

Evans

. Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 2002; 83(11): 1559–1561.

15.

Tadić

Đajić

Grgić

, et al. Association of body mass index with progression and prediction of multiple sclerosis. Script Med 2020; 51: 34–40.

16.

Haycock

Burgess

Wade

, et al. Best (but oft-forgotten) practices: The design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 2016; 103(4): 965–978.

17.

Davey Smith

Hemani

. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Human Molecular Genetics 2014; 23: R89–R98.

18.

Consortium IMSG ANZgene IIBDGC,et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019; 365: eaav7188.

19.

Sawcer

Hellenthal

Pirinen

, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

20.

Kister

Kantarci

. Multiple sclerosis severity score: Concept and applications. Mult Scler 2020; 26(5): 548–553.

21.

Cho

Haycock

Sanderson

, et al. Exploiting horizontal pleiotropy to search for causal pathways within a Mendelian randomization framework. Nat Commun 2020; 11: 1–13.

22.

Hemani

Tilling

Davey Smith

. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 2017; 13: e1007081.

23.

Hemani

Bowden

Davey Smith

. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Human Molecular Genetics 2018; 27: R195–R208.

24.

Bowden

Holmes

. Meta-analysis and Mendelian randomization: A review. Res Synth Method 2019; 10: 486–496.

25.

Bowden

Del Greco

Minelli

, et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. International Journal of Epidemiology 2016; 45: 1961–1974.

26.

Swerdlow

Kuchenbaecker

Shah

, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol 2016; 45(5): 1600–1616.

27.

Bowden

Davey Smith

Haycock

, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40(4): 304–314.

28.

Burgess

Davey Smith

Davies

, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2019; 4: 186.

29.

Greco

MFD

Minelli

Sheehan

, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med 2015; 34: 2926–2940.

30.

Burgess

Thompson

. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol 2015; 181: 251–260.

31.

Bowden

Spiller

Del Greco

, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the radial plot and radial regression. Int J Epidemiol 2018; 47: 1264–1278.

32.

Sanderson

. Multivariable Mendelian randomization and mediation. Cold Sp Harbor Persp Med 2021; 11: a038984.

33.

Benjamini

Hochberg

. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc: Ser B (Methodol) 1995; 57: 289–300.

34.

Schorr

Dichtel

Gerweck

, et al. Sex differences in body composition and association with cardiometabolic risk. Biol Sex Differ 2018; 9: 1–10.

35.

Ponti

Santoro

Mercatelli

, et al. Aging and imaging assessment of body composition: From fat to facts. Front Endocrinol 2020; 10: 861.

36.

Paternoster

Tilling

Davey Smith

. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. PLoS Genet 2017; 13(10): e1006944.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB